

PSMA PET – Practice, Pitfalls and Potential

Charles Goh

Singapore General Hospital, Singapore

Prostate specific membrane antigen (PSMA) PET CT has proven to be a highly sensitive and specific imaging modality for prostate cancer, both in the settings of recurrence and staging. It shows high sensitivity, even with low PSA values less than 1.0 ng/ml. In centers where it is available, it has rapidly supplanted choline-based tracers as the PET agent of choice in evaluating prostate cancer. However, despite its name, uptake in both benign and malignant non-prostatic lesions occurs, which readers need to be aware of to avoid error. As PSMA PET is a relatively new imaging modality, its clinical role has yet to be fully defined. As more data emerges, we foresee its future integration into clinical guidelines for staging, recurrence, response evaluation and pre-therapy evaluation for PSMA therapy.